EUCTR2004-005015-29-DE进行中（未招募）不适用
A multicenter double-blind randomized study to investigate the efficacy and tolerability of three doses of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal neovascularisation, a major risk factor of corneal graft rejection.
es Laboratoires CTRS0 个研究点目标入组 100 人开始时间: 2005年9月29日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Men or non-pregnant women.
- •At least 18 years old.
- •Suffering from keratitis or keratouveitis due to contact lens microbial keratitis, bacteria or other microorganisms, viruses, protozoa, immunologic diseases, trauma or prior surgery, alkali burns, graft rejection or degenerative disorders.
- •Evidence of documented progression of neovascularisation during a period of minimum 2 weeks and maximum 3 months before inclusion
- •Patients who are able to understand the protocol and give informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who cannot communicate reliably with the investigator.
- •Patients who are unlikely to cooperate with the requirements of the study
- •Patients who are unwilling and/or unable to give informed consent
- •Patients suffering from a life-threatening progressive disease
- •Patients participating in another clinical study
- •Patients who have used any other investigational drugs within 1 month of first dosing.
研究者
相似试验
招募中
1 期
A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD)Delayed Sleep-Wake Phase Disorder (DSWPD)MedDRA version: 21.0Level: LLTClassification code 10041013Term: Sleep-wake schedule disorderSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-005475-40-DEVanda Pharmaceuticals Inc.300
招募中
1 期
A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD)Delayed Sleep-Wake Phase Disorder (DSWPD)MedDRA version: 21.0Level: LLTClassification code 10041013Term: Sleep-wake schedule disorderSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-005475-40-ATVanda Pharmaceuticals Inc.300
进行中（未招募）
1 期
A study to investigate the safety and efficacy of a six month oral treatment with a twice daily dose of BAY 1142524 in comparison to placebo in patients with reduced left-ventricular ejection fraction after acute myocardial infarction.EUCTR2016-002167-33-CZBayer AG185
进行中（未招募）
1 期
A study to investigate the safety and efficacy of a six month oral treatment with a twice daily dose of BAY 1142524 in comparison to placebo in patients with reduced left-ventricular ejection fraction after acute myocardial infarctioeft-ventricular dysfunction after acute myocardial infarctionEUCTR2016-002167-33-ESBayer AG140
进行中（未招募）
1 期
A study to investigate the safety and efficacy of a six month oral treatment with a twice daily dose of BAY 1142524 in comparison to placebo in patients with reduced left-ventricular ejection fraction after acute myocardial infarctioEUCTR2016-002167-33-DEBayer AG185